Medical Network News, September 28: Recently, the National Medical Insurance Administration led the first round of centralized procurement of high-end consumables in public hospitals across the country. Heart stents are the only variety and are expected to be completed in November. According to a report in Caijing magazine, the National Medical Insurance Administration has been preparing for this action for two years, and it will eventually fall into the heart stent market that can fully bid for the purpose of squeezing out the moisture in the price and not leaving room for "rebates."

　　 How much water is the heart stent that made the Medical Insurance Bureau "control the price"? Sullivan’s 2019 survey showed that a domestic heart stent has an ex-factory price of about 3,000 yuan and a hospital price of about 27,000; an imported heart stent has a CIF price of about 6,000 yuan, and the hospital’s price can reach 38,000 yuan.

　　 "China Cardiovascular Disease Report 2018" shows that in China, 1 in 5 people is a cardiovascular patient. The number of reported cardiovascular disease patients in China is as high as 2.9 billion. According to other data, the number of PCI operations nationwide in 2019 exceeded 1.03 million, and the use of stents exceeded 1.6 million.

　　 It is reported that, driven by high demand and high profits, cardiovascular medicine, which uses high-value consumables such as heart stents and pacemakers, has long become a high incidence of hospital bribery.

　　According to Caijing magazine, in the second half of 2019, five cardiovascular experts were deprived of the horse in Jiangsu Province, and eight hospital bribery cases were sentenced nationwide to be related to cardiovascular consumables.

As early as 2012, cardiologist Professor Hu Dayi publicly stated at the "14th National Conference on Cardiovascular Diseases" that the problem of the abuse of heart stents in China has been quite serious. "Many patients were put in more than three at a time. Some were even put into more than a dozen". He said that few people need more than three heart stents, unless other parts of the surgery cause damage to the compensatory placement, most of the placement is an abuse.

　　 When reviewing the government work report in 2015, Zhong Nanshan also criticized the disorderly installation of heart stents in public hospitals. He said that some of them even installed 5 heart stents on a patient in order to "generate income", which is simply crazy.

　　The country has launched "soul bargaining", or it may be promoted nationwide

　　 On September 10, at a symposium on centralized procurement of medicines and high-value medical consumables hosted by Han Zheng, member of the Standing Committee of the Political Bureau of the Central Committee and Vice Premier of the State Council, the heart stent was personally "named" by the vice premier.

　　Han Zheng emphasized that it is necessary to accelerate the expansion of the scope of centralized procurement, focus on solving the problems of inconsistent standards and unclear classification of medical consumables, and do a good job in the procurement of centralized cardiac stents.

　　Actually, in July this year, the National Medical Insurance Bureau publicly solicited opinions on the release of the National Organization for Centralized Procurement of Coronary Stents (Draft for Comment). With the publication of this article, the centralized procurement of coronary stents by the state has been unified, and centralized procurement in all provinces has ceased. Some insiders predict that the issuance of this article may bring about tremendous changes to the future pattern of coronary intervention industry.

　　Before the entry of the national team, at the end of July 2019, the General Office of the State Council issued the "Reform Plan for Governance of High-value Medical Consumables", which is the benchmark plan for the treatment of high-value consumables. Subsequently, Jiangsu, Shanxi and many other places have already started the provincial-level procurement of coronary stents. For example, in Jiangsu Province, there are 55 public hospitals holding groups to negotiate with companies.

　　 The results of the negotiation show that after Jiangsu's trial of centralized procurement in 2019, the average price of selected stents in Jiangsu Province has dropped by 51.01%, and the largest drop is 66.07%. Among them, Minimally Invasive Medical, which has the greatest price reduction, dropped the 14,000 yuan stent to 7,000 yuan, and its 7,799 yuan stent in the low-price range was reduced to 3,400 yuan.

Song Fenglian, Director of the Pharmaceutical Price and Bidding and Purchasing Department of the Shanxi Provincial Medical Insurance Bureau, said: “With the 68 medical institutions trading in volume, the selected products dropped by an average of 52.98%, with the highest drop of 69.12% and the lowest drop of 40.2%. The province can save a year The purchase and use cost of cardiac coronary stents is about 200 million yuan."

　　 Industry insiders predict that in the future, national-level purchases will be even greater, similar to the "soul bargaining" of drugs or reappearance. At the same time, the experience of various provinces with volume procurement may be promoted.